Clinical trial
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
NCT00129727 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00129727 |
|---|---|
| Title | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) |
| Official title | Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Women and Infants Hospital of Rhode Island |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Carboplatin, Bevacizumab |
| Enrollment | 62 |
| Start date | Jun 1, 2005 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Aug 12, 2005 |
| Last update posted | Jun 1, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: